- Home
- NDSN vs BBIO Comparison
NDSN vs BBIO Comparison
Compare NDSN & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NDSN | BBIO |
|---|---|---|
| Founded | 1935 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.1B | 14.2B |
| IPO Year | 1998 | 2019 |
Fundamental Metrics
Financial Performance| Metric | NDSN | BBIO |
|---|---|---|
| Price | $280.40 | $70.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 25 |
| Target Price | ★ $320.80 | $86.33 |
| AVG Volume (30 Days) | 270.3K | ★ 2.3M |
| Earning Date | 05-27-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.17% | N/A |
| EPS Growth | ★ 4.93 | N/A |
| EPS | ★ 2.38 | N/A |
| Revenue | ★ $2,254,668,000.00 | $502,076,000.00 |
| Revenue This Year | $7.71 | $89.45 |
| Revenue Next Year | $4.96 | $73.78 |
| P/E Ratio | $117.65 | ★ N/A |
| Revenue Growth | 9.08 | ★ 126.26 |
| 52 Week Low | $187.89 | $31.77 |
| 52 Week High | $305.28 | $84.94 |
Technical Indicators
Market Signals| Indicator | NDSN | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 54.32 | 43.63 |
| Support Level | $265.04 | $69.62 |
| Resistance Level | $287.04 | $78.96 |
| Average True Range (ATR) | 4.86 | 3.99 |
| MACD | 0.56 | -0.79 |
| Stochastic Oscillator | 55.84 | 14.62 |
Price Performance
Historical ComparisonAbout NDSN Nordson Corporation
Nordson manufactures equipment (including pumps, valves, dispensers, applicators, filters, and pelletizers) used for dispensing adhesives, coatings, sealants, and other materials. The firm serves a diverse range of end markets including packaging, medical, electronics, and industrial. Nordson's business is organized into three segments: industrial precision solutions, medical and fluid solutions, and advanced technology solutions. The company generated approximately $2.8 billion in revenue in its fiscal 2025.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.